glp 1 substance abuse GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though GLP-1 drugs linked to lower

J Biol Chem 263: 1347513478, 1988

That can be due to dehydration from not drinking enough and from side effects like vomiting and diarrhea

Early Research in Autoimmune Disease & Fibromyalgia What It Shows and Why Its Limited Fibromyalgia: Early Signals, No Conclusions Some observational reports describe symptom improvements (pain, fatigue, opioid use) in people taking GLP-1 medications, but limitations are consistent: non-randomized design, small samples, and confounding from weight loss, sleep, and metabolic improvements

Any early weight changes typically reflect fluid loss rather than significant fat loss, which occurs more gradually over subsequent weeks and months with dose escalation

A plausible explanation for this finding is that these patients may have used these medications for managing their condition and subsequently experienced weight loss as an unintended side effect [54]

These injections work by regulating appetite, helping patients feel fuller longer, and reducing cravings